

Siegfried Success Story : Celgene

Tailor-made partnership with Celgene

Celgene Corporation has chosen Siegfried Ltd as one of its principal manufacturers of active pharmaceutical ingredients. Celgene is one of the top five biotech companies in the world based on market capitalization. Our agreement with Celgene is tailor-made to their needs with roughly 5% of our production capacity in Zofingen, Switzerland being put at their disposal. The deal revolves around their second drug, the multiple myeloma treatment Revlimid, which was gaining in sales through approvals in more markets and additional uses.

Because Revlimid is an analog of the human teratogen thalidomide, the U.S. company wanted to maintain control of drug production by conducting the final steps itself. Siegfried provides intermediates, testing, and support services.